Fragiele X Syndroom

Fragile X Syndrome is one of the leading monogenic causes of intellectual disability and autism, and named after the aberrant (‘fragile’) form of the X-chromosome in these individuals.

Fragile X Syndrome is caused by lack of the fragile X mental retardation protein (FMRP), resulting from an (200 +) expansion of the trinucleotide (CGG) repeat at the beginning (5’ untranslated region) of the fragile X mental retardation 1 gene (FMR1). This causes the loss of FMRP protein.

The Fragile X gene was identified at Erasmus MC (Verkerk, Cell, 1991). The Fragile X gene encodes a protein that is called FMRP1 (Fragile X Mental Retardation Protein). This protein binds mRNA which is crucial in the regulation of protein synthesis following stimulation of group 1 metabotropic glutamate receptors (mGluRs) in dendritic spines. Activation of these receptors, especially the mGluR5 receptor, leads to local translation of specific mRNAs into proteins. It is believed that FMRP plays an important role in the translation of these mRNAs, and that loss of FMRP results in excess protein synthesis.

Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late onset neurodegenerative disorder causing tremor, ataxia, brain pathology, cognitive loss, dementia and early death in some individuals. Like in Fragile X Syndrome, these individuals carry a mutation in the FMR1 gene. But in this case, it is a Fragile X pre-mutation (an expanded CGG repeat between 50-200). In contrast to Fragile X Syndrome, FXTAS is hypothesized to be caused by a gain-of-function mechanism, i.e. the pre-mutation gives rise to a toxic protein. A hallmark of FXTAS neuropathology in postmortem brain tissue is the presence of ubiquitin-positive intranuclear aggregates in both neurons and astrocytes.

The first mouse model of Fragile X Syndrome was generated at the department of Clinical Genetics, Erasmus MC. Using behavioural and molecular/morphological paradigms in both Fmr1 mice and cultured primary neurons or iPSCs, our research aims to identify possible targets for therapeutic intervention. Social behavior of Fmr1 knockout mice is the primary outcome measure in the preclinical mouse studies. In addition, new strategies are explored using combination therapy. Development and evaluation of successful therapeutic intervention strategies (drugs, combination therapy) from our preclinical work can lead to new clinical trials at ENCORE in patients with Fragile X Syndrome.

For FXTAS research, there is a need to define critical ages when pathology begins, development windows when the disease may be halted or reversed, and the cellular and molecular mechanisms that may serve as therapeutic targets for patients with FXTAS. To address these important needs, we have developed powerful state-of-the-art in vitro and in vivo models of FXTAS, including: primary neurons, mouse and zebrafish models.

Müller AR, (2024) Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials. BMC Psychiatry. Pubmed

Lubbers K, (2022) Autism Symptoms in Children and Young Adults With Fragile X Syndrome, Angelman Syndrome, Tuberous Sclerosis Complex, and Neurofibromatosis Type 1: A Cross-Syndrome Comparison. Front Psychiatry. Pubmed

Ottenhoff MJ, (2020) Considerations for Clinical Therapeutic Development of Statins for Neurodevelopmental Disorders. eNeuro. 7; 1-5. Pubmed

Van Remmerden MC, et al. (2020) Growing up with Fragile X Syndrome: Concerns and Care Needs of Young Adult Patients and Their Parents. J Autism Dev Disord. Pubmed

Zeidler S, Fragile X Syndrome: new therapeutic strategies. Tijdschr Psychiatr. 60(5); 338-42 Link

Zeidler S, (2017) Leidraad voor diagnostiek en behandeling van kinderen met het Fragiele X Syndroom. Expertisecentrum ENCORE. Link

van der Vaart T, (2015) Treatment of Cognitive Deficits in Genetic Disorders: A Systematic Review of Clinical Trials of Diet and Drug Treatments. JAMA Neurol 72; 1052–60. Pubmed

Pop, A.S. et al. (2013) Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development. Psychopharmacology (Berl.) Pubmed

de Esch, C.E.F. et al. (2013) Translational endpoints in fragile X syndrome. Neurosci Biobehav Rev. Pubmed

Pop, A.S. et al. (2012) Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant. Psychopharmacology (Berl.) Pubmed

Vinueza Veloz, M.F. et al. (2012) The effect of an mGluR5 inhibitor on procedural memory and avoidance discrimination impairments in Fmr1 KO mice. Genes Brain Behav 11, 325–331. Pubmed

Castrén, E. et al. (2012) Treatment of neurodevelopmental disorders in adulthood. J Neurosci 32, 14074–14079. Link

Levenga, J. et al. (2011) AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol Dis 42, 311–317. Pubmed

Levenga, J. et al. (2011) Subregion-specific dendritic spine abnormalities in the hippocampus of Fmr1 KO mice. Neurobiol Learn Mem 95, 467–472. Pubmed

Levenga, J. et al. (2010) Potential therapeutic interventions for fragile X syndrome. Trends Mol Med 16, 516–527. Pubmed

Brouwer, J.R. et al. (2009) The FMR1 gene and fragile X-associated tremor/ataxia syndrome. Am. J. Med Genet B Neuropsychiatr Genet, 150, 782–798. Pubmed

Levenga, J. et al. (2009) Ultrastructural analysis of the functional domains in FMRP using primary hippocampal mouse neurons. Neurobiol Dis 35, 241–250. Pubmed

Van’t Padje, S. et al. (2009) Reduction in fragile X related 1 protein causes cardiomyopathy and muscular dystrophy in zebrafish. J. Exp. Biol. 212, 2564–2570. Pubmed

Brouwer, J.R. et al. (2008) CGG-repeat length and neuropathological and molecular correlates in a mouse model for fragile X-associated tremor/ataxia syndrome. J Neurochem 107, 1671–1682. Pubmed

Smit, A.E. et al. (2008) Savings and extinction of conditioned eyeblink responses in fragile X syndrome. Genes Brain Behav 7, 770–777. Pubmed

de Vrij, F.M.S. et al. (2008) Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis 31, 127–132. Pubmed

Brouwer, J.R. et al. (2008) Altered hypothalamus-pituitary-adrenal gland axis regulation in the expanded CGG-repeat mouse model for fragile X-associated tremor/ataxia syndrome. Psychoneuroendocrinology 33, 863–873. Pubmed

Govaerts, L.C.P. et al. (2007) Exceptional good cognitive and phenotypic profile in a male carrying a mosaic mutation in the FMR1 gene. Clin Genet 72, 138–144. Pubmed

Brouwer, J.R. et al. (2007) Elevated Fmr1 mRNA levels and reduced protein expression in a mouse model with an unmethylated Fragile X full mutation. Exp Cell Res 313, 244–253. Pubmed

Mientjes, E.J. et al. (2006) The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo. Neurobiol Dis 21, 549–555. Pubmed

Koekkoek, S.K.E. et al. (2005) Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome. Neuron 47, 339–352. Pubmed

van ’t Padje, S. et al. (2005) Characterisation of Fmrp in zebrafish: evolutionary dynamics of the fmr1 gene. Dev. Genes Evol. 215, 198–206. Pubmed

Blonden, L. et al. (2005) Two members of the Fxr gene family, Fmr1 and Fxr1, are differentially expressed in Xenopus tropicalis. Int. J. Dev. Biol. 49, 437–441. Pubmed

Stoyanova, V. et al. (2004) Loss of FMR1 hypermethylation in somatic cell heterokaryons. FASEB J. 18, 1964–1966. Pubmed

Schrier, M. et al. (2004) Transport kinetics of FMRP containing the I304N mutation of severe fragile X syndrome in neurites of living rat PC12 cells. Exp Neurol 189, 343–353. Pubmed

Mientjes, E.J. et al. (2004) Fxr1 knockout mice show a striated muscle phenotype: implications for Fxr1p function in vivo. Hum Mol Genet 13, 1291–1302. Pubmed

De Diego Otero, Y. et al. (2002) Transport of fragile X mental retardation protein via granules in neurites of PC12 cells. Mol Cell Biol 22, 8332–8341. Pubmed

Willemsen, R. et al. (2002) Timing of the absence of FMR1 expression in full mutation chorionic villi. Hum Genet 110, 601–605. Pubmed

Bontekoe, C.J.M. et al. (2002) Knockout mouse model for Fxr2: a model for mental retardation. Hum Mol Genet 11, 487–498. Pubmed

Bontekoe, C.J. et al. (2001) Instability of a (CGG)98 repeat in the Fmr1 promoter. Hum Mol Genet 10, 1693–1699. Pubmed

Willemsen, R. et al. (2000) Twin sisters, monozygotic with the fragile X mutation, but with a different phenotype. J Med Genet 37, 603–604. Pubmed

Bakker, C.E. et al. (2000) Immunocytochemical and biochemical characterization of FMRP, FXR1P, and FXR2P in the mouse. Exp Cell Res 258, 162–170. Pubmed

Tamanini, F. et al. (2000) The fragile X-related proteins FXR1P and FXR2P contain a functional nucleolar-targeting signal equivalent to the HIV-1 regulatory proteins. Hum Mol Genet 9, 1487–1493. Pubmed

Willemsen, R. et al. (1999) Noninvasive test for fragile X syndrome, using hair root analysis. Am J Hum Genet 65, 98–103. Pubmed

de Vries, B.B. et al. (1999) Screening for the fragile X syndrome among the mentally retarded: a clinical study. The Collaborative Fragile X Study Group. J Med Genet 36, 467–470. Pubmed

Tamanini, F. et al. (1999) Different targets for the fragile X-related proteins revealed by their distinct nuclear localizations. Hum Mol Genet 8, 863–869. Pubmed

de Vries, B.B. et al. (1999) Dilemmas in counselling females with the fragile X syndrome. J Med Genet 36, 167–170. Pubmed

Wildhagen, M.F. et al. (1999) Efficacy of cascade testing for fragile X syndrome. J Med Screen 6, 70–76. Pubmed

de Vries, B.B. et al. (1998) Screening with the FMR1 protein test among mentally retarded males. Hum Genet 103, 520–522. Pubmed

Verheij, C. et al. (1993) Characterization and localization of the FMR-1 gene product associated with fragile X syndrome. Nature 363, 722–724. Pubmed

Reyniers, E. et al. (1993) The full mutation in the FMR-1 gene of male fragile X patients is absent in their sperm. Nat Genet 4, 143–146. Pubmed

Verkerk, A.J. et al. (1993) Alternative splicing in the fragile X gene FMR1. Hum Mol Genet 2, 399–404. Pubmed

De Boulle, K. et al. (1993) A point mutation in the FMR-1 gene associated with fragile X mental retardation. Nat Genet 3, 31–35. Pubmed

de Vries, B.B. et al. (1993) Mental status and fragile X expression in relation to FMR-1 gene mutation. Eur J Hum Genet 1, 72–79. Pubmed

Willems, P.J. et al. (1992) Segregation of the fragile X mutation from an affected male to his normal daughter. Hum Mol Genet 1, 511–515. Pubmed

Verkerk, A.J. et al. (1992) Intragenic probe used for diagnostics in fragile X families. Am J Med Genet 43, 192–196. Pubmed

Oostra, B.A. and Verkerk, A.J. (1992) The fragile X syndrome: isolation of the FMR-1 gene and characterization of the fragile X mutation. Chromosoma 101, 381–387. Pubmed

Faust, C.J. et al. (1992) Genetic mapping on the mouse X chromosome of human cDNA clones for the fragile X and Hunter syndromes. Genomics 12, 814–817. Pubmed

Verkerk, A.J. et al. (1991) Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65, 905–914. Pubmed